Author Topic: (Abst.) Inebilizumab (MEDI-551)--results from phase 1 study  (Read 39 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8244
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Inebilizumab (MEDI-551)--results from phase 1 study
« on: February 01, 2019, 09:40:35 pm »

Abstract, "Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of MS:  Results from a phase 1, randomised, placebo-controlled, escalating  intravenous and subcutaneous dose study" in Multiple Sclerosis Journal (February 1, 2019; first published November 2017):

https://journals.sagepub.com/doi/abs/10.1177/1352458517740641
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
52 Views
Last post August 07, 2016, 09:34:11 am
by agate
0 Replies
53 Views
Last post November 16, 2016, 08:37:33 am
by agate
1 Replies
83 Views
Last post November 14, 2018, 04:04:14 pm
by agate
0 Replies
48 Views
Last post September 20, 2017, 02:55:23 pm
by agate
0 Replies
37 Views
Last post September 30, 2018, 07:31:15 pm
by agate